Journal Article
. 2015 Jun; 24(1):367-376.
doi: 10.1007/s00520-015-2779-5.

Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany

Hartmut Link 1 J Nietsch 2 M Kerkmann 2 P Ortner 3 Supportive Care Group (ASORS) of the German Cancer Society (DKG)  
Affiliations
  • PMID: 26081593
  •     35 References
  •     10 citations

Abstract

Purpose: Febrile neutropenia (FN) after chemotherapy increases complications, morbidity, risk of death, reduction of dose delivery and impairs quality of life. Primary granulocyte-colony stimulating factor (G-CSF) prophylaxis after chemotherapy is recommended in the guideline (GL) if the risk of FN is high (≥20%) or intermediate (≥10-20%) with additional risk factors. This study evaluated the implementation of G-CSF GL.

Patients And Methods: Sample size of the survey was calculated at 2% of the incidences of malignant lymphoma, breast cancer, and lung cancer in Germany in 2006. Patients were documented retrospectively over three to nine cycles of chemotherapy and FN risk ≥10%. Professional physician profiles were analyzed by classification and regression tree analysis (CART).

Results: One hundred ninety-five hematologists-oncologists and pulmonologists and gynecologists specialized in oncology documented data of 666 lung cancer patients, 286 malignant lymphoma patients, and 976 breast cancer patients, with 7805 chemotherapy cycles; 85.1% of physicians claimed adhering to G-CSF GL. Adherence to GL in all high-FN-risk chemotherapy cycles was 15.4% in lung cancer, 84.5% in malignant lymphoma, and 85.6% in breast cancer, and in all intermediate-FN-risk chemotherapy cycles, lung cancer it was 38.8%, malignant lymphoma it was 59.4%, and breast cancer it was 49.3%. G-CSF was overused without additional patient risk factors in 7.2% lung cancer cycles, 16.8% malignant lymphoma cycles, and 17.6% breast cancer cycles. The CART analysis split pulmonologists and other specialists, with the latter adhering more to GL. Pulmonologists, trained less than 22.5 years, adhered better to GL, as did also gynecologists or hematologists-oncologists with professional experience less than 8.1 years.

Conclusions: Acceptance of and adherence to G-CSF GL differed between lung cancer, lymphoma, and breast cancer. Physicians overestimate their adherence to the GL. Physicians adhering to the GL can be characterized.

Keywords: Adherence; Febrile neutropenia; G-CSF guidelines; Implementation; Physicians’ professional profile.

Critical evaluation of the scientific content in clinical practice guidelines.
Zaid M Abdelsattar, Bradley N Reames, +2 authors, Sandra L Wong.
Cancer, 2014 Nov 08; 121(5). PMID: 25376967    Free PMC article.
Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes.
Arnold L Potosky, Jennifer L Malin, +4 authors, Jane C Weeks.
J Natl Cancer Inst, 2011 Jun 15; 103(12). PMID: 21670423    Free PMC article.
Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic.
Geralyn E Waters, Patricia Corrigan, Mandy Gatesman, Thomas J Smith.
J Oncol Pract, 2013 Aug 15; 9(4). PMID: 23942922    Free PMC article.
Review.
Why don't physicians follow clinical practice guidelines? A framework for improvement.
M D Cabana, C S Rand, +4 authors, H R Rubin.
JAMA, 1999 Oct 27; 282(15). PMID: 10535437
Highly Cited. Review.
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
Thomas J Smith, James Khatcheressian, +19 authors, Antonio C Wolff.
J Clin Oncol, 2006 May 10; 24(19). PMID: 16682719
Highly Cited.
Impact of cancer supportive care pathways compliance on emergency department visits and hospitalizations.
Eugene D Kreys, Ted Y Kim, Andrew Delgado, Jim M Koeller.
J Oncol Pract, 2014 May 20; 10(3). PMID: 24839275
Colony-stimulating factors for febrile neutropenia during cancer therapy.
Charles L Bennett, Benjamin Djulbegovic, LeAnn B Norris, James O Armitage.
N Engl J Med, 2013 Mar 22; 368(12). PMID: 23514290    Free PMC article.
Review.
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.
Nicole M Kuderer, David C Dale, +2 authors, Gary H Lyman.
Cancer, 2006 Apr 01; 106(10). PMID: 16575919
Highly Cited.
Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer.
Nicole Hébert-Croteau, Jacques Brisson, +3 authors, Ginette Martin.
J Clin Oncol, 2004 Aug 04; 22(18). PMID: 15289491
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.
Nicole M Kuderer, David C Dale, Jeffrey Crawford, Gary H Lyman.
J Clin Oncol, 2007 Jul 20; 25(21). PMID: 17634496
Highly Cited. Systematic Review.
A way forward on the medically appropriate use of white cell growth factors.
Thomas J Smith, Bruce E Hillner.
J Clin Oncol, 2012 Mar 01; 30(14). PMID: 22370327    Free PMC article.
Review.
The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials.
G H Lyman, D C Dale, +5 authors, J Crawford.
Ann Oncol, 2013 Jun 22; 24(10). PMID: 23788754    Free PMC article.
Systematic Review.
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.
G Bonadonna, P Valagussa, +2 authors, C Brambilla.
N Engl J Med, 1995 Apr 06; 332(14). PMID: 7877646
Highly Cited.
Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines.
C Falandry, M Campone, +2 authors, G Freyer.
Eur J Cancer, 2010 Aug 25; 46(13). PMID: 20732287
Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy.
Gary H Lyman, Nicole M Kuderer, +4 authors, David C Dale.
Cancer, 2011 Apr 22; 117(9). PMID: 21509769    Free PMC article.
Risk of mortality in patients with cancer who experience febrile neutropenia.
Gary H Lyman, Shannon L Michels, +3 authors, Jingbo Yu.
Cancer, 2010 Aug 18; 116(23). PMID: 20715160
Granulocyte colony-stimulating factors used in clinical practice: PoloNord Registry-Based Cohort Italian Study.
Daniele Fagnani, Luciano Isa, +13 authors, POLONORD Group.
Tumori, 2014 Oct 25; 100(5). PMID: 25343541
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.
Erik von Elm, Douglas G Altman, +4 authors, STROBE Initiative.
PLoS Med, 2007 Oct 19; 4(10). PMID: 17941714    Free PMC article.
Highly Cited. Review.
Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients With Metastatic Solid Tumors.
Derek Weycker, Xiaoyan Li, +4 authors, Gary H Lyman.
J Oncol Pract, 2014 Dec 11; 11(1). PMID: 25491042
Examining and addressing evidence-practice gaps in cancer care: a systematic review.
Jamie Bryant, Allison Boyes, +3 authors, Rae Fry.
Implement Sci, 2014 Mar 29; 9(1). PMID: 24666544    Free PMC article.
Systematic Review.
Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study.
L Jolis, F Carabantes, +8 authors, PRAXIS Study Group.
Eur J Cancer Care (Engl), 2013 Jun 05; 22(4). PMID: 23730920
Granulocyte colony-stimulating factor (G-CSF) patterns of use in cancer patients receiving myelosuppressive chemotherapy.
Mi Rim Choi, Craig A Solid, +4 authors, Thomas J Arneson.
Support Care Cancer, 2014 Feb 05; 22(6). PMID: 24492928
Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer.
Genevieve M Boland, George J Chang, +7 authors, Janice N Cormier.
Cancer, 2013 Jan 03; 119(8). PMID: 23280510    Free PMC article.
Critical evaluation of oncology clinical practice guidelines.
Bradley N Reames, Robert W Krell, Sarah N Ponto, Sandra L Wong.
J Clin Oncol, 2013 Jun 12; 31(20). PMID: 23752105    Free PMC article.
Systematic Review.
The GuideLine Implementability Appraisal (GLIA): development of an instrument to identify obstacles to guideline implementation.
Richard N Shiffman, Jane Dixon, +4 authors, Ryan O'Connell.
BMC Med Inform Decis Mak, 2005 Jul 29; 5. PMID: 16048653    Free PMC article.
Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study.
J L Pujol, J P Daurès, +10 authors, T Le Chevalier.
J Natl Cancer Inst, 2001 Feb 22; 93(4). PMID: 11181777
The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Fever and neutropenia: the early years.
Gerald P Bodey.
J Antimicrob Chemother, 2009 Apr 23; 63 Suppl 1. PMID: 19372179
Review.
Guideline concordant therapy prolongs survival in HER2-positive breast cancer patients: results from a large population-based cohort of a cancer registry.
E C Inwald, O Ortmann, +4 authors, M Klinkhammer-Schalke.
Biomed Res Int, 2014 Apr 30; 2014. PMID: 24779005    Free PMC article.
Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.
Nicole M Kuderer, Gary H Lyman.
J Natl Cancer Inst, 2011 Jun 15; 103(12). PMID: 21670422    Free PMC article.
Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers.
Sudeep J Karve, Gregory L Price, +3 authors, Lee Bowman.
BMC Health Serv Res, 2014 Nov 14; 14. PMID: 25392276    Free PMC article.
Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline.
Christopher R Flowers, Jerome Seidenfeld, +8 authors, Scott D Ramsey.
J Clin Oncol, 2013 Jan 16; 31(6). PMID: 23319691
Highly Cited.
Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO).
J J Vehreschild, A Böhme, +9 authors, J Bohlius.
Ann Oncol, 2014 Mar 19; 25(9). PMID: 24631945
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
M S Aapro, J Bohlius, +10 authors, European Organisation for Research and Treatment of Cancer.
Eur J Cancer, 2010 Nov 26; 47(1). PMID: 21095116
Highly Cited. Systematic Review.
Attitudes toward and use of cancer management guidelines in a national sample of medical oncologists and surgeons.
Reshma Jagsi, Grace Huang, +5 authors, Sarah T Hawley.
J Natl Compr Canc Netw, 2014 Mar 04; 12(2). PMID: 24586082
Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practice.
K Krzemieniecki, P Sevelda, +7 authors, J Maenpaa.
Support Care Cancer, 2013 Oct 25; 22(3). PMID: 24154740    Free PMC article.
Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone.
Claudio Cerchione, Lucio Catalano, +6 authors, Fabrizio Pane.
Support Care Cancer, 2016 Oct 28; 24(12). PMID: 27726031    Free PMC article.
Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience.
Claudio Cerchione, Amalia De Renzo, +5 authors, Marco Picardi.
Support Care Cancer, 2016 Nov 05; 25(3). PMID: 27812763    Free PMC article.
Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.
Matti Aapro, Ralph Boccia, +10 authors, Vicente Valero.
Support Care Cancer, 2017 Aug 27; 25(11). PMID: 28842778    Free PMC article.
Review.
A questionnaire survey of pharmacists regarding the clinical practice guidelines for the appropriate use of granulocyte-colony stimulating factors.
Tetsuya Sasaki, Yasuhisa Kato, +7 authors, Katsuyuki Kiura.
J Pharm Health Care Sci, 2018 Jan 30; 4. PMID: 29375887    Free PMC article.
Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study).
Henri Roché, Jean-Christophe Eymard, +6 authors, Alain Toledano.
BMC Cancer, 2018 Nov 18; 18(1). PMID: 30445935    Free PMC article.
Guideline adherence in bone-targeted treatment of cancer patients with bone metastases in Germany.
Hartmut Link, Ingo Diel, +3 authors, Associations Supportive Care in Oncology (AGSMO), Medical Oncology (AIO), Urological Oncology (AUO), within the German Cancer Society (DKG) and the German Osteooncological Society (DOG).
Support Care Cancer, 2019 Aug 15; 28(5). PMID: 31410600    Free PMC article.
Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure.
Paul Cornes, Pere Gascon, Arnold G Vulto, Matti Aapro.
BioDrugs, 2020 Apr 02; 34(3). PMID: 32232676    Free PMC article.
Review.
Real-world use of granulocyte colony-stimulating factor in ambulatory breast cancer patients: a cross-sectional study.
Florence Van Ryckeghem, Chloë Haverbeke, +5 authors, Simon Van Belle.
Support Care Cancer, 2018 Aug 14; 27(3). PMID: 30099601
G-CSF guideline adherence in Germany, an update with a retrospective and representative sample survey.
Hartmut Link, Markus Kerkmann, +2 authors, Working Groups Supportive Care (ASORS now AGSMO) and Medical Oncology (AIO) within the German Cancer Society (DKG).
Support Care Cancer, 2018 Oct 31; 27(4). PMID: 30374765    Free PMC article.
CD151 promotes Colorectal Cancer progression by a crosstalk involving CEACAM6, LGR5 and Wnt signaling via TGFβ1.
Tao Yang, Huibing Wang, +13 authors, Wei Zhang.
Int J Biol Sci, 2021 Mar 27; 17(3). PMID: 33767593    Free PMC article.